Managing skin side effects from EGFR inhibitors for metastatic colorectal cancer

For people living with metastatic colorectal cancer (mCRC), EGFR inhibitors can be an important part of treatment. While these therapies can be effective, they commonly cause skin-related side effects that can affect comfort, confidence, and quality of life. Skin toxicities are manageable, especially when addressed early. In many cases, proactive skin care can help reduce the severity of symptoms and allow patients to stay on treatment longer.

Why do EGFR inhibitors cause skin problems?

EGFR (epidermal growth factor receptor) proteins are found not only on cancer cells, but also on healthy skin, hair follicles, and nails. When EGFR inhibitors block these receptors, they can disrupt normal skin cell growth and repair.

As a result, patients may develop:

• Acne-like rash (papulopustular rash)
• Dry or itchy skin
• Cracked skin on the hands and feet
• Nail inflammation
• Increased sun sensitivity
• Hair texture changes

The most common side effect is an acneiform rash, which often appears on the face, scalp, chest, or upper back within the first few weeks of treatment.

Step 1: Start with preventive skin care

Experts now recommend starting a preventive skin care routine before or at the beginning of EGFR inhibitor therapy rather than waiting for symptoms to appear.

A preventive routine may include:

• Applying a fragrance-free moisturizer twice daily
• Using broad-spectrum sunscreen (SPF 30 or higher) every day
• Avoiding hot showers and harsh soaps
• Switching to gentle, alcohol-free cleansers
• Wearing protective clothing and limiting sun exposure

Many oncologists also prescribe preventive oral antibiotics at the start of treatment because they can help reduce inflammation and lower the risk of severe rash.

Before starting treatment, it can also help to:

• Discuss any pre-existing skin conditions with your care team
• Take baseline photos to monitor skin changes over time
• Establish care with a dermatologist familiar with cancer-related skin toxicities if possible

Step 2: Monitor symptoms early

Skin reactions from EGFR inhibitors can worsen quickly if left untreated, so early communication with your care team is important. Symptoms are typically graded based on how extensive they are and whether they interfere with daily activities.

Mild symptoms

• Small bumps or redness
• Mild itching or tenderness
• Limited impact on daily life

Mild symptoms are often managed with continued moisturizing, sunscreen use, and topical medications.

Moderate symptoms

• More widespread rash
• Increased discomfort
• Emotional or physical impact on daily activities

At this stage, your oncology team may prescribe topical steroids, oral antibiotics, or additional supportive treatments.

Severe symptoms

• Painful or widespread rash
• Skin cracking or infection
• Difficulty with self-care or daily functioning

Severe reactions sometimes require temporary treatment interruption or dose adjustments, although many patients can restart therapy once symptoms improve.

You should contact your care team promptly if you notice:

• Yellow crusting
• Drainage or oozing
• Fever
• Significant pain
• Rapid worsening of the rash

These symptoms may suggest infection or more serious inflammation requiring medical treatment.

Step 3: Treat flares promptly

Even with preventive care, flare-ups can still happen. Early treatment can help prevent symptoms from becoming severe.

It’s important to avoid over-the-counter acne treatments containing active ingredients like benzoyl peroxide, salicylic acid, or retinoids unless specifically recommended by your provider. These products are designed for traditional acne and can further irritate skin already weakened by EGFR-targeted therapy.

Skin toxicity may be linked to treatment response

Some studies have found that developing an acne-like rash is associated with better treatment outcomes, likely because it reflects effective EGFR inhibition. However, not everyone who responds to treatment develops a rash, so its absence does not mean the treatment isn’t working. Patients should never stop or reduce treatment on their own without speaking to their oncology team.

What’s new in research

Researchers are also making progress toward better treatments for EGFR inhibitor-related skin toxicities. In early clinical studies, an investigational topical gel called LUT014 improved rash severity and quality of life while allowing many patients to continue their cancer treatment. Although more research is needed before it becomes widely available, these findings highlight the growing focus on helping patients manage side effects without compromising the effectiveness of their cancer therapy.

Long-term skin care matters

Because EGFR inhibitors are often given over many months, ongoing skin care becomes an important part of treatment.

Keeping a symptom journal, taking photos of skin changes, and reporting new symptoms early can help care teams adjust supportive treatments before side effects become more difficult to manage.

Many cancer centers now encourage collaboration between oncology and dermatology specialists, sometimes called “oncodermatology,” to help patients maintain quality of life during treatment.

With proactive care, many patients are able to successfully manage skin toxicities while continuing treatment for mCRC.

Connect with an Outcomes4Me oncology nurse practitioner at no charge through the Outcomes4Me app, using the “Ask Outcomes4Me” button.